Kevin Gibbs to Risk Assessment
This is a "connection" page, showing publications Kevin Gibbs has written about Risk Assessment.
Connection Strength
0.050
-
Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, Shapiro NI, Ginde AA, Douin DJ, Prekker ME, Brown SM, Peltan ID, Gong MN, Mohamed A, Khan A, Exline MC, Files DC, Gibbs KW, Stubblefield WB, Casey JD, Rice TW, Grijalva CG, Hager DN, Shehu A, Qadir N, Chang SY, Wilson JG, Gaglani M, Murthy K, Calhoun N, Monto AS, Martin ET, Malani A, Zimmerman RK, Silveira FP, Middleton DB, Zhu Y, Wyatt D, Stephenson M, Baughman A, Womack KN, Hart KW, Kobayashi M, Verani JR, Patel MM. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged =65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):674-679.
Score: 0.034
-
Arnaoutakis GJ, George TJ, Robinson CW, Gibbs KW, Orens JB, Merlo CA, Shah AS. Severe acute kidney injury according to the RIFLE (risk, injury, failure, loss, end stage) criteria affects mortality in lung transplantation. J Heart Lung Transplant. 2011 Oct; 30(10):1161-8.
Score: 0.017